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moral antigens. Conservation of blood
during surgery will always be important
because of the shortages of donor blood,
the risks associated with the use of allo-
genic blood products, and the costs of
these products.
At this stage, the outcome measured
needs to be better studied in a larger group
of patients to determine whether a benefi-
cial effect is achieved when the cause is
simply a new-onset decrease in hematocrit
during CPB that requires the action of
blood transfusion.
How Can We Define the
Dimensions for Safe Intraoperative
Hematocrit Level?
In the context of a study trial, all variables
in a scientific study must be controlled ex-
cept for a single variable that is being stud-
ied. This is an incredible task, but it can be
solved with a national task force among
many regional centers and coordinated in
the most organized fashion. Recruitment of
centers that are indifferent to institutional
experience is key for eliminating bias. The
center with established excellence in surgi-
cal outcome among The Society of Tho-
racic Surgeons risk stratification subgroups
will minimize technically dependent out-
come variables and maximize the weighted
effect of a single variable— hematocrit.
The patient population description should
include elective surgical patients who re-
quire primary or redo CPB coronary, valve,
or both types of surgery; who lack hema-
tologic causes for anemia; who have a
well-defined etiology of disease process;
and who lack prior blood transfusions in
the last 3 months, including a well-defined
level of comorbidity.
Selection of Hematocrits
Given the already available data in the lit-
erature, it is important to chose 2 pathways,
each performed randomly at each collabo-
rating surgical unit, given that neither the
perfusionist nor the surgeon will be
blinded. This will mathematically accom-
modate a range of preoperative hematocrits
to better define absolute and relative risk or
benefit to the population sample after trans-
fusion or not. The 2 pathways are (1) trans-
fusing for hematocrits below a discrete
value (20%, 25%, and 30%) and (2) trans-
fusing for hematocrits when an absolute
difference in CPB hematocrits (5, 10, 15,
and 20 integers) is documented during sur-
gery.
The volume of blood transfused should
be held constant, and 1 unit of allogeneic
blood should be sufficient except in rare
circumstances. Should the next hematocrit
level respond, no further blood transfusion
should be given, yet further transfusion
will be given if levels keep decreasing.
Time from acknowledging the hematocrit
level after the intervention (blood transfu-
sion) will need to be further defined at
discussion committees, among other vari-
ables, especially regarding triggers for pre-
operative CPB, postoperative CPB, and in-
tensive care unit periods with respect to 4
important groups of patients—those with
left ventricular dysfunction, recent myocar-
dial infarction, congestive heart failure, and
incomplete revascularization— because
such groups require a higher hematocrit
level.
A host of other blood product trans-
fusion, perfusion, and operative vari-
ables—including age of blood trans-
fused; priming volume; length of
operation; amount of blood transfusion;
type of blood transfused (eg, leukocyte
depleted, cytomegalovirus status, and al-
logeneic vs predonated autologous
blood); pump run; blood-primed pump;
use of preoperative antiplatelets, antico-
agulants, and antifibrinolytics; duration
of CPB; temperature control (hypother-
mia and normothermia); volume of crys-
talloids and colloids infused and reason
for infusion; and volume of other blood
products infused—will need to be ad-
justed after consultation with a consor-
tium of perfusionists and hematologists
who are experienced in this field.
Also, a similar policy for transfusion
should be adopted after surgery to avoid
the potential influence of postoperative
transfusion on clinical outcome. Outcome,
including neurological outcome and sur-
vival, should be temporally and qualita-
tively documented particularly early after
surgery and several years later.
Overall, there must be a safe range of
hematocrits for each patient in adult and
pediatric patients. Available studies re-
main largely observational and cannot
adjust for the effects of all the confound-
ers. In the interim, conservative use of
blood products in heart surgery is war-
ranted because of the infectious and non-
infectious complications of allogeneic
blood transfusion.
Jeffrey H. Shuhaiber, MD
Department of Surgery
University of Illinois at Chicago
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Reply to the Editor:
We would like to thank Dr Jonas for his
comments on our recent article.1 Our study
was a prospective, observational study, and
the patients had an uncomplicated course in
which the criteria for red blood cell trans-
fusion included anemia with a hematocrit
level of less than 15% during bypass and
20% after bypass. Jonas and associates2
conducted a randomized study, and they
concluded that a higher hematocrit strategy
was safe for psychomotor development in
infants. Habib and associates3 retrospec-
tively analyzed the surgical outcomes from
their 6-year experience and concluded that
there was a strong association between se-
verity of hemodilution during cardiopul-
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monary bypass and serious complications,
particularly when the nadir hematocrit de-
creased to less than 22%.
In these 3 studies, the age, weight, se-
riousness of the disease, previous cerebro-
vascular accident, duration of circulatory
arrest, and percentage of emergency sur-
gery were completely different. Therefore,
it might be very difficult to compare the
results and determine an appropriate he-
matocrit level during cardiopulmonary by-
pass, especially for surgical cases using
deep hypothermic circulatory arrest. Re-
garding the backgrounds of the patients,
our study group was considered to be the
best candidates for hemodilution during
cardiopulmonary bypass. Transfusion has
been proven to be an effective therapy for
hemodilutional anemia. However, this ther-
apy may cause severe adverse effects. Al-
though there were no adverse effects in our
study group, we agree with Dr Jonas that a
prospective randomized study should be
performed not only in adults, but also in
children with simple congenital heart de-
fects to determine the appropriate hemato-
crit level that improves a patient’s chance
for the most favorable outcome.
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Extrapleural pneumonectomy for
malignant mesothelioma: Should
pericardium be resected routinely?
To the Editor:
We read with interest the article by Sugar-
baker and colleagues1 in the July issue of
the Journal. This study reports their exten-
sive experience with the management of
complications occurring after extrapleural
pneumonectomy (EPP) done mainly for
malignant mesothelioma. It is clear from
the Sugarbaker article that technical com-
plications might arise from the resection
and replacement of the pericardium with a
patch, such as size mismatch, improper in-
sertion and suturing, or inadequate fenes-
tration. Three percent of their patients had
cardiac arrest, 2.7% had constrictive phys-
iology caused by inflammatory epicarditis,
3.6% had tamponade, and 44.2% had atrial
fibrillation.
Although we recognize the importance of
Sugarbaker’s work in studying specific com-
plications of EPP and reporting the largest
series to date, we would like to emphasize a
particular technical point that might prove
useful in some patients. Recently, we have
been surprised that some patients with stage I
or II malignant mesothelioma receiving in-
duction chemotherapy before EPP presented
at the operation with a pericardium macro-
scopically free of disease. In those patients
we have taken random biopsy specimens of
the pericardium and have preserved them.
Histopathology confirmed the absence of
pericardial invasion in all patients. In such
patients with a macroscopically normal peri-
cardium, we suggest taking frozen sections of
the pericardium and preserving them if the
frozen sections are negative. Although we do
agree that pericardium has to be resected in
most patients with malignant pleural me-
sothelioma, it is likely that with the adoption
of induction chemotherapy before EPP2 and
refinement of diagnostic techniques, such as
positron emission tomography and computed
tomography, more patients will be operated
on with the possibility of preserving their
native pericardium, thereby reducing the in-
cidence of cardiac complications, reducing
the operative time, and facilitating the an-
chorage of the diaphragmatic patch.
We would also like to mention that chy-
lothorax is another potential complication
of EPP, with a recent article reporting an
18.7% incidence.2 Although no postopera-
tive chylothorax has been reported in the
series by Sugarbaker et al,1 we would like
to re-emphasize the importance of prophy-
lactic thoracic duct ligation during right-
sided procedures.
Loïc Lang-Lazdunski, MD, PhD, FRCS
Carol Tan, MRCS
Tom Treasure, MD, MS, FRCS
Department of Cardiothoracic Surgery
Guy’s Hospital
London, United Kingdom
References
1. Sugarbaker DJ, Jaklitsch MT, Bueno R, Rich-
ards W, Lukanich J, Mentzer SJ, et al. Pre-
vention, early detection, and management of
complications after 328 consecutive ex-
trapleural pneumonectomies. J Thorac Car-
diovasc Surg. 2004;128:138-46.
2. Weder W, Kestenholz P, Taverna C, Lardi-
nois D, Jerman M, Stahel RA. Neoadjuvant
chemotherapy followed by extrapleural pneu-
monectomy in malignant pleural mesotheli-
oma. J Clin Oncol. 2004;22:3451-7.
doi:10.1016/j.jtcvs.2004.11.034
Reply to the Editor:
The primary goal of extrapleural pneumo-
nectomy in mesothelioma is to perform a
complete macroscopic cytoreduction. Rou-
tine pericardiectomy is an important step in
achieving this goal. The issue of pericardial
resection and reconstruction from the mor-
bidity standpoint is a higher atrial fibrilla-
tion rate, the risk of cardiac herniation from
a poorly constructed patch, tamponade
from a tight patch, and epicarditis.
Our high rate of atrial fibrillation com-
pared with that seen in other reports that
use similar resection of the pericardium
stems from our policy of monitoring all
patients with telemetry until discharge
from the hospital. Opening the pericardium
is only one of the multiple causes of atrial
fibrillation. Entry into the pericardium with
multiple random biopsies would also result
in a higher atrial fibrillation rate or at least
not a significant decrease in those rates.
Cardiac herniation or tamponade from a
poorly done pericardial reconstruction
would be avoided by not resecting the peri-
cardium. These are not common events,
however, and were more prevalent during
our earlier experience. However, from an
oncologic perspective, it would not be pru-
dent to risk a good cytoreduction, even in
the setting of a few negative random biopsy
specimens. It is this group of patients with
early disease that would benefit the most
from the most aggressive surgical interven-
tion.
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